BRPI0922022A2 - Composições farmacêuticas, kits, métodos de prevenção ou tratamento de doenças neurais do indivíduo e respectivos usos - Google Patents

Composições farmacêuticas, kits, métodos de prevenção ou tratamento de doenças neurais do indivíduo e respectivos usos

Info

Publication number
BRPI0922022A2
BRPI0922022A2 BRPI0922022A BRPI0922022A BRPI0922022A2 BR PI0922022 A2 BRPI0922022 A2 BR PI0922022A2 BR PI0922022 A BRPI0922022 A BR PI0922022A BR PI0922022 A BRPI0922022 A BR PI0922022A BR PI0922022 A2 BRPI0922022 A2 BR PI0922022A2
Authority
BR
Brazil
Prior art keywords
kits
prevention
individual
treatment
methods
Prior art date
Application number
BRPI0922022A
Other languages
English (en)
Inventor
Yang Yoon-Sun
Il Oh Won
Wook Chang Jong
Yeon Kim Ju
Original Assignee
Medipost Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medipost Co Ltd filed Critical Medipost Co Ltd
Publication of BRPI0922022A2 publication Critical patent/BRPI0922022A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0619—Neurons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0665—Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1352—Mesenchymal stem cells
    • C12N2502/1358—Bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1352—Mesenchymal stem cells
    • C12N2502/137—Blood-borne mesenchymal stem cells, e.g. Msc from umbilical cord blood

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)

Abstract

COMPOSIÇÕES FARMACÊUTICAS, KITS, MÉTODOS DE PREVENÇÃO OU TRATAMENTO DE DOENÇAS NEURAIS DO INDIVÍDUO E RESPECTIVOS USOS. São proporcionados uma composição farmacêutica para prevenção e tratamento de uma doença neural incluindo pelo menos um selecionado a partir do grupo que consiste em células-tronco mesenquimais (MSCs), uma solução de cultura das MSCs, activina A, PF4, decorina, galectina 3, GDF15, glipican 3, MFRP, ICAMS, IGEBPY7, PDGF-AA, SPARCL1, trombospondina-1, WISP1, progranulina, IL-4, um fator induzindo a expressão do mesmo e qualquer combinação dos mesmos e um método para isso.
BRPI0922022A 2008-11-14 2009-11-16 Composições farmacêuticas, kits, métodos de prevenção ou tratamento de doenças neurais do indivíduo e respectivos usos BRPI0922022A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US19329308P 2008-11-14 2008-11-14
KR20080113465 2008-11-14
KR1020090072114A KR20100054711A (ko) 2008-11-14 2009-08-05 간엽 줄기세포 또는 이의 배양액을 포함하는 신경질환의 예방 또는 치료용 조성물
PCT/KR2009/006712 WO2010056075A2 (en) 2008-11-14 2009-11-16 Composition comprising mesenchymal stem cells or culture solution of mesenchymal stem cells for the prevention or treatment of neural diseases

Publications (1)

Publication Number Publication Date
BRPI0922022A2 true BRPI0922022A2 (pt) 2017-07-11

Family

ID=42279397

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0922022A BRPI0922022A2 (pt) 2008-11-14 2009-11-16 Composições farmacêuticas, kits, métodos de prevenção ou tratamento de doenças neurais do indivíduo e respectivos usos

Country Status (11)

Country Link
US (1) US10238692B2 (pt)
EP (1) EP2365816B1 (pt)
JP (2) JP5650122B2 (pt)
KR (4) KR20100054711A (pt)
CN (2) CN102281883A (pt)
AU (1) AU2009314797B2 (pt)
BR (1) BRPI0922022A2 (pt)
CA (1) CA2743620C (pt)
MX (1) MX2011005118A (pt)
MY (1) MY179052A (pt)
WO (1) WO2010056075A2 (pt)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101541954B (zh) 2006-11-30 2012-12-26 Medipost株式会社 含有人脐带血衍生的间充质干细胞的组合物诱导神经前体细胞或神经干细胞分化和增殖为神经细胞的用途
US9358320B2 (en) 2008-04-25 2016-06-07 Allosource Multi-layer tissue patches
US9480549B2 (en) 2008-04-25 2016-11-01 Allosource Multi-layer tissue patches
KR20100054711A (ko) * 2008-11-14 2010-05-25 메디포스트(주) 간엽 줄기세포 또는 이의 배양액을 포함하는 신경질환의 예방 또는 치료용 조성물
WO2011106476A1 (en) * 2010-02-25 2011-09-01 Abt Holding Company Modulation of microglia activation
WO2012060517A1 (ko) * 2010-11-05 2012-05-10 하이스템(주) Ｃｄ45가 발현되는 중간엽 줄기세포를 유효성분으로 포함하는 신경질환 예방 및 치료용 의약 조성
JP6312436B2 (ja) * 2010-11-16 2018-04-18 ニューロダイン ライフ サイエンシズ インコーポレイテッドＮｅｕｒｏｄｙｎ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｉｎｃ． ネプリライシンの発現および活性を増大させるための方法および医薬組成物
AU2012211519B2 (en) * 2011-02-02 2015-07-30 Medipost Co., Ltd. Use of ICAM-1 for prevention or treatment of neurological diseases
WO2012164137A1 (es) 2011-05-30 2012-12-06 Fundación Investigación En Regeneración Del Sistema Nervioso Células madre y células de la estirpe neural derivadas de la glía envolvente olfatoria, y sus aplicaciones
EP2723364A1 (en) * 2011-06-24 2014-04-30 National University of Ireland Galway Cell secreted proteins for the treatment of myocardial infarction
JPWO2013039000A1 (ja) * 2011-09-13 2015-03-26 孝広 落谷 アルツハイマー病の予防または治療のための医薬品
CN103087983A (zh) * 2011-10-27 2013-05-08 北京清美联创干细胞科技有限公司 一种药物诱导肌肉间充质干细胞增殖和分化的方法及应用
US9162011B2 (en) 2011-12-19 2015-10-20 Allosource Flowable matrix compositions and methods
KR20130104924A (ko) * 2012-03-16 2013-09-25 (주)히스토스템 항바이러스 작용을 갖는 제대혈 다분화능 줄기세포 유래의 세포활성화 물질을 포함하는 조성물 및 이의 제조방법
EP2659897A1 (en) * 2012-05-02 2013-11-06 Philipps-Universität Marburg Stem cell derived composition for the treatment of acute injury and degenerative diseases
US10493104B2 (en) 2013-02-20 2019-12-03 Samsung Life Public Welfare Foundation Composition for treating inflammatory brain diseases which includes stem cell as active ingredient
AU2014248873B2 (en) 2013-03-13 2017-03-23 Allosource Fascia fibrous compositions and methods for their use and manufacture
CA2899713C (en) 2013-03-15 2022-07-19 Allosource Cell repopulated collagen matrix for soft tissue repair and regeneration
WO2014141219A1 (en) * 2013-03-15 2014-09-18 Blue Horizon International Llc Umbilical cord blood derived stem cell transplantation for the treatment of neural disorder
US20140286910A1 (en) * 2013-03-19 2014-09-25 Nikolai Tankovich Stem cells and methods incorporating environmental factors as a means for enhancing stem cell proliferation and plasticity
KR101455933B1 (ko) * 2013-05-28 2014-10-31 가톨릭대학교 산학협력단 인간골수유래 중간엽줄기세포와 미노사이클린 병용투여를 통한 다발성경화증 치료제 및 치료방법
CN103599129A (zh) * 2013-11-07 2014-02-26 唐明淇 一种人干细胞组合物在制备用于治疗阿尔茨海默症的药物中的用途
KR102161901B1 (ko) 2013-12-06 2020-10-05 알로소스 조직의 시트를 건조하는 방법
US20160143950A1 (en) * 2013-12-22 2016-05-26 Nikolai Tankovich Stem cells and stem cell factors for inhibiting the progression of alzheimer's disease
CN103751228B (zh) * 2014-01-27 2016-04-20 贵州神奇药物研究院 治疗老年痴呆的药物及其制备方法
EP3701969A1 (en) 2014-10-31 2020-09-02 NGM Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
CN104758923A (zh) * 2015-03-11 2015-07-08 黑龙江天晴干细胞股份有限公司 一种治疗神经损伤的干细胞制剂及其制备方法
US11707488B2 (en) 2015-08-28 2023-07-25 Rohto Pharmaceutical Co., Ltd. ROR1-positive mesenchymal stem cells and method for preparing same, pharmaceutical composition containing ROR1-positive mesenchymal stem cells and method for preparing same, and method for preventing or treating disease using ROR1-positive mesenchymal stem cells
US11628190B2 (en) * 2015-08-28 2023-04-18 University Of South Florida Plasma derived from human umbilical cord blood for the treatment of neurodegenerative disorders
US11179420B2 (en) * 2016-04-27 2021-11-23 Rohto Pharmaceutical Co., Ltd. Method for treating a disease, comprising administering mesenchymal stem cells or culture supernatant thereof to a subject
WO2017188457A1 (ja) * 2016-04-28 2017-11-02 北海道公立大学法人札幌医科大学 シナプス形成剤
US20240002459A1 (en) * 2016-07-14 2024-01-04 Emory University Granulin Compositions and Uses Related Thereto
IL264825B (en) 2016-08-14 2022-08-01 Univ Ramot Mesenchymal cell-derived exosomes to treat neurological disorders
US10772986B2 (en) 2017-01-26 2020-09-15 Allosource Fascia fibrous compositions and methods for their use and manufacture
US20200108099A1 (en) 2017-02-15 2020-04-09 Rohto Pharmaceutical Co., Ltd. Therapeutic agent for pulmonary fibrosis, ptprr expression-promotor, and kit for treatment of pulmonary fibrosis
CN116590227A (zh) 2017-03-03 2023-08-15 日本乐敦制药株式会社 间充质干细胞和肝疾病治疗剂
WO2018159432A1 (ja) 2017-03-03 2018-09-07 ロート製薬株式会社 間葉系幹細胞及び医薬組成物
JPWO2018164228A1 (ja) 2017-03-08 2020-01-09 ロート製薬株式会社 Ｒｏｒ１陽性の間葉系幹細胞を含有する、線維症を伴う疾患の予防又は処置のための医薬組成物、及びその調製方法、並びにｒｏｒ１陽性の間葉系幹細胞を用いる線維症を伴う疾患の予防又は処置方法
WO2018225440A1 (ja) 2017-06-09 2018-12-13 国立大学法人大阪大学 拡張型心筋症治療剤
CN107320495A (zh) * 2017-06-19 2017-11-07 北正赛欧（北京）生物科技有限公司 用于促进细胞损伤修复的组合物及其应用
WO2019139137A1 (ja) 2018-01-12 2019-07-18 国立大学法人大阪大学 重層扁平上皮細胞の正常分化・成熟促進剤、上皮疾患治療剤及び重層扁平上皮細胞の正常分化・成熟促進方法
KR102053868B1 (ko) 2018-01-31 2020-01-22 가톨릭대학교 산학협력단 하비갑개 유래 중간엽 줄기세포를 유효성분으로 포함하는 퇴행성 신경계질환 예방 또는 치료용 약학적 조성물
GB201803010D0 (en) * 2018-02-26 2018-04-11 Royal Holloway & Bedford New College Neurodegenerative disorders
WO2019203555A1 (ko) * 2018-04-17 2019-10-24 한국생명공학연구원 Ｐｒｏｇｒａｎｕｌｉｎ 단백질을 포함하는 간질환의 예방 또는 치료용 조성물
US20210220340A1 (en) 2018-06-21 2021-07-22 The Asan Foundation Composition for prevention or treatment of neurodegenerative disease
CN109182260A (zh) * 2018-09-11 2019-01-11 邵勇 一种体外培养胎膜间充质干细胞的方法
WO2020181411A1 (zh) * 2019-03-08 2020-09-17 玛旺干细胞医学生物科技股份有限公司 间充质干细胞在预防或治疗情绪疾病上的医药用途
PH12022551598A1 (en) * 2019-12-23 2023-11-20 Denali Therapeutics Inc Progranulin variants
CN111635886A (zh) * 2020-07-02 2020-09-08 成都恩喜医疗管理有限公司 一种间充质干细胞的制备方法与应用
WO2022049977A1 (ja) * 2020-09-03 2022-03-10 株式会社ツーセル 中枢神経疾患の治療用組成物、中枢神経疾患の治療用組成物の製造方法および中枢神経疾患の治療用製剤の製造方法
JP2023540096A (ja) * 2020-09-08 2023-09-21 ロングエバーオン インコーポレイテッド アロジェニック間葉系幹細胞によるアルツハイマー病の治療
WO2022091086A1 (en) * 2020-10-26 2022-05-05 Hadasit Medical Research Services And Development Ltd. Mesenchymal stem cells and their culture
WO2022176735A1 (ja) 2021-02-22 2022-08-25 ロート製薬株式会社 糖尿病の予防及び／又は治療剤
CA3215311A1 (en) 2021-04-01 2022-10-06 The Regents Of The University Of California Genetic modification of mammalian cells to confer resistance to csf1r antagonists
WO2023054918A1 (ko) * 2021-09-30 2023-04-06 주식회사 디자인셀 네프릴라이신을 과발현하는 줄기세포, 이의 배양액 및 이들로부터 분리된 엑소좀을 유효성분으로 포함하는 인지기능장애의 예방 또는 치료용 약학적 조성물
KR102919897B1 (ko) * 2021-09-30 2026-01-30 주식회사 디자인셀 네프릴라이신을 과발현하는 줄기세포, 이의 배양액 및 이들로부터 분리된 엑소좀을 유효성분으로 포함하는 인지기능장애의 예방 또는 치료용 약학적 조성물
WO2023080413A1 (ko) 2021-11-02 2023-05-11 주식회사 디자인셀 줄기세포 배양액 및 이로부터 분리된 엑소좀을 유효성분으로 포함하는 안구 질환의 예방 또는 치료용 약학적 조성물
WO2023140347A1 (ja) 2022-01-24 2023-07-27 国立大学法人広島大学 精子処理用組成物、精子運動性改善剤、精子受精能保持剤、精子運動性改善方法及び精子受精能保持方法
JPWO2023140348A1 (pt) 2022-01-24 2023-07-27
WO2023154953A1 (en) * 2022-02-14 2023-08-17 Ngm Biopharmaceuticals, Inc. Gdf15 polypeptides for treating and preventing autoimmune diseases
US20250290037A1 (en) * 2022-04-27 2025-09-18 The Regents Of The University Of California Pathology-responsive recombinant cells and uses thereof
CN115192609A (zh) * 2022-05-10 2022-10-18 湖南中南大学湘雅口腔医院 间充质干细胞在制备治疗抑郁症的药物中的应用
WO2024043232A1 (ja) 2022-08-25 2024-02-29 ロート製薬株式会社 腎疾患治療剤、腎機能改善剤
CN120167010A (zh) 2022-11-01 2025-06-17 国立大学法人广岛大学 精子处理用组合物、精子运动性改善剂、精子受精能力保持剂、精子运动性改善方法及精子受精能力保持方法
KR20250096828A (ko) 2022-11-01 2025-06-27 고쿠리츠다이가쿠호진 히로시마다이가쿠 자궁 처리용 조성물, 자궁 환경 개선제, 착상 보조제, 배아 이식액, 정자 이식액 및 착상률 개선제
CN116115738B (zh) * 2023-02-22 2024-09-03 重庆大学 细胞因子Igfbp7在制备治疗小鼠老年性肌肉萎缩的药物中的应用
WO2025100424A1 (ja) * 2023-11-10 2025-05-15 国立大学法人 東京大学 急性脳症治療剤及び急性脳症の治療方法
CN117547597A (zh) * 2023-11-28 2024-02-13 四川大学华西医院 基因Wisp1在制备调控MSCs抗衰老表型药物中的应用
CN117384857B (zh) * 2023-12-08 2024-03-19 上海兴瑞一达生物科技有限公司 一种pf4基因修饰的间充质干细胞外泌体及其应用
CN119733100B (zh) * 2025-03-05 2025-05-30 首都医科大学 一种梅克尔软骨细胞分泌蛋白组合及其制备方法和应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8013A (en) * 1851-04-01 Improvement in wheat-fans
US7354588B1 (en) 1987-05-04 2008-04-08 Dana Farber Cancer Institute Functional derivatives of ICAM-1 with altered ability to bind LFA-1 or HRV
US5733542A (en) * 1990-11-16 1998-03-31 Haynesworth; Stephen E. Enhancing bone marrow engraftment using MSCS
US20030060398A1 (en) * 1997-09-19 2003-03-27 Gluckman Peter David Neuronal rescue agent
US5837576A (en) 1997-10-31 1998-11-17 Vanguard International Semiconductor Corporation Method for forming a capacitor using a silicon oxynitride etching stop layer
US6900299B1 (en) 1999-03-11 2005-05-31 University Of South Florida Interrupting the interaction of intercellular adhesion molecule-1 and respiratory syncytial virus for prevention and treatment of infection
ES2251974T3 (es) 1999-03-12 2006-05-16 The Board Of Trustees Of The Leland Stanford Junior University Vacunacion de adn para el tratamiento de enfermedades autoinmunes.
US6372494B1 (en) * 1999-05-14 2002-04-16 Advanced Tissue Sciences, Inc. Methods of making conditioned cell culture medium compositions
JP2002543841A (ja) * 1999-05-17 2002-12-24 バイオファーム ゲゼルシャフト ツア バイオテクノロジシェン エントヴィックルング ウント ツム フェルトリーブ フォン ファルマカ エムベーハー ＴＧＦ−βスーパーファミリーの新規のメンバーであるＧＤＦ―１５の神経保護特性
US20040208858A1 (en) 2000-04-12 2004-10-21 Gihan Tennekoon Therapeutic uses for mesenchymal stromal cells
EP1302534A4 (en) 2000-06-26 2004-06-16 Renomedix Inst Inc CELL FRACTION WITH CELLS WHICH ARE ABLE TO DIFFERENTIATE IN NERVOUS CELLS
US20040037775A1 (en) 2000-08-01 2004-02-26 Siahaan Teruna J. Leukocyte internalized peptide-drug conjugates
US7560280B2 (en) 2000-11-03 2009-07-14 Kourion Therapeutics Gmbh Human cord blood derived unrestricted somatic stem cells (USSC)
KR100449141B1 (ko) 2001-04-19 2004-09-21 (주)라이프코드 간엽 간세포를 신경세포로 분화시키는 방법
ES2287447T3 (es) 2002-02-19 2007-12-16 Medipost, Co., Ltd. Metodos de aislamiento y expansion del cultivo de celulas troncales/madre mesenquimatosas a partir de sangre del cordon umbilical, y metodo de diferenciacion de celulas troncales/madre mesenquimatosas derivadas de sangre del cordon umbilical en diversos tejidos mesenquimatosos.
US20090192105A1 (en) 2002-02-20 2009-07-30 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF INTERCELLULAR ADHESION MOLECULE (ICAM) GENE EXPRESSION USING SHORT INTERFERING NUCELIC ACID (siNA)
US7732203B2 (en) 2002-08-17 2010-06-08 Ajoll University Industry Cooperation Foundation Method for transdifferentiating mesenchymal stem cells into neuronal cells
US20040203142A1 (en) 2003-04-14 2004-10-14 Reliance Life Sciences Pvt. Ltd. Growth of neural precursor cells using umbilical cord blood serum and a process for the preparation thereof for therapeutic purposes
JP5099288B2 (ja) 2003-09-09 2012-12-19 学校法人慶應義塾 神経幹細胞の生存及び／又は増殖及び神経突起伸張を促進する方法並びに促進剤、神経幹細胞を含む医薬組成物、検定方法、スクリーニング方法
US20060094064A1 (en) 2003-11-19 2006-05-04 Sandip Ray Methods and compositions for diagnosis, stratification, and monitoring of alzheimer's disease and other neurological disorders in body fluids
JP4027359B2 (ja) 2003-12-25 2007-12-26 キヤノン株式会社 マイクロ揺動体、光偏向器、画像形成装置
EP3461884B1 (en) * 2004-03-22 2025-05-28 Mesoblast International Sàrl Mesenchymal stem cells and uses therefor
WO2007054128A1 (en) 2005-11-14 2007-05-18 Dominion Pharmakine S.L. Novel inhibitors of the lfa-1/icam-1 interaction, and uses thereof
EP1767617A1 (en) * 2005-09-26 2007-03-28 Letizia Mazzini Mesenchymal stem cells isolation and expansion method and uses thereof
US20070253931A1 (en) 2006-01-12 2007-11-01 Osiris Therapeutics, Inc. Use of mesenchymal stem cells for treating genetic diseases and disorders
KR100792184B1 (ko) 2006-05-12 2008-01-07 재단법인서울대학교산학협력재단 개의 제대혈, 태반 및 개 태아의 심장 유래 다분화능 성체줄기세포, 그 제조방법 및 이를 함유하는 세포 치료제
KR20080049562A (ko) * 2006-11-30 2008-06-04 가톨릭대학교 산학협력단 제대혈 유래 간엽 줄기세포를 유효성분으로 포함하는 신경손상 질환 치료제
KR20100054711A (ko) 2008-11-14 2010-05-25 메디포스트(주) 간엽 줄기세포 또는 이의 배양액을 포함하는 신경질환의 예방 또는 치료용 조성물

Also Published As

Publication number Publication date
JP5893084B2 (ja) 2016-03-23
CN107412263A (zh) 2017-12-01
EP2365816A2 (en) 2011-09-21
MY179052A (en) 2020-10-26
JP2014240388A (ja) 2014-12-25
AU2009314797B2 (en) 2012-10-11
KR101114800B1 (ko) 2012-03-13
JP5650122B2 (ja) 2015-01-07
KR20100054711A (ko) 2010-05-25
CA2743620A1 (en) 2010-05-20
KR20110087263A (ko) 2011-08-02
US10238692B2 (en) 2019-03-26
EP2365816B1 (en) 2017-06-28
KR101533989B1 (ko) 2015-07-06
AU2009314797A1 (en) 2010-05-20
EP2365816A4 (en) 2013-05-15
MX2011005118A (es) 2011-09-26
KR20100054731A (ko) 2010-05-25
WO2010056075A3 (en) 2010-09-30
CA2743620C (en) 2017-08-15
WO2010056075A2 (en) 2010-05-20
KR20100054759A (ko) 2010-05-25
JP2012508733A (ja) 2012-04-12
US20110262393A1 (en) 2011-10-27
CN102281883A (zh) 2011-12-14

Similar Documents

Publication Publication Date Title
BRPI0922022A2 (pt) Composições farmacêuticas, kits, métodos de prevenção ou tratamento de doenças neurais do indivíduo e respectivos usos
Kim et al. Hesperetin alleviates the inhibitory effects of high glucose on the osteoblastic differentiation of periodontal ligament stem cells
Zhou et al. The effect of quercetin on the osteogenesic differentiation and angiogenic factor expression of bone marrow-derived mesenchymal stem cells
Wu et al. A Bi‐lineage conducive scaffold for osteochondral defect regeneration
Kang et al. Cellular and molecular stimulation of adipose‐derived stem cells under hypoxia
Shi et al. Modulation of chondrocyte motility by tetrahedral DNA nanostructures
Rezai Rad et al. Impact of tissue harvesting sites on the cellular behaviors of adipose‐derived stem cells: Implication for bone tissue engineering
Huang et al. Rho/Rho-associated protein kinase signaling pathway‑mediated downregulation of runt-related transcription factor 2 expression promotes the differentiation of dental pulp stem cells into odontoblasts
JP6751465B2 (ja) クロモン誘導体の上皮間葉移行抑制活性を利用した線維症予防及び治療用医薬組成物としての新規用途
Onizuka et al. ZBTB16 as a downstream target gene of osterix regulates osteoblastogenesis of human multipotent mesenchymal stromal cells
BRPI0608109A2 (pt) tratamento de distúrbios ósseos
Peng et al. LncRNA‐AK137033 inhibits the osteogenic potential of adipose‐derived stem cells in diabetic osteoporosis by regulating Wnt signaling pathway via DNA methylation
Choi et al. Enhanced osteogenesis by collagen‐binding peptide from bone sialoprotein in vitro and in vivo
Xu et al. LncRNA‐TWIST1 promoted osteogenic differentiation both in PPDLSCs and in HPDLSCs by inhibiting TWIST1 expression
BRPI0905687A8 (pt) composto da fórmula i ou i', composição farmacêutica, método de tratamento de um paciente com uma doença, uso do composto
Liu et al. BMP9 is a potential therapeutic agent for use in oral and maxillofacial bone tissue engineering
Brito et al. MicroRNA-138: an emerging regulator of skeletal development, homeostasis, and disease
Wrona et al. Derivation and characterization of porcine vocal fold extracellular matrix scaffold
Song et al. Remodeling the senescent microenvironment for promoting osteoporotic tendon-to-bone healing via synergizing senolytic quercetin and aligned nanowire-structured hydrogels
Jiang et al. Long non-coding RNAs in bone formation: Key regulators and therapeutic prospects
Paulose et al. Spinal cord regeneration by modulating bone marrow with neurotransmitters and Citicholine: Analysis at micromolecular level
Park et al. Enhanced osteogenesis of human urine-derived stem cells by direct delivery of 30Kc19α–Lin28A protein
Kamm et al. Adipose stromal cells in the human rotator cuff are resistant to fibrotic microenvironmental cues
Zainal Ariffin et al. In vitro chondrogenesis transformation study of mouse dental pulp stem cells
Zhang et al. Synergistic effects of BMP9 and miR‐548d‐5p on promoting osteogenic differentiation of mesenchymal stem cells

Legal Events

Date Code Title Description
B15I Others concerning applications: loss of priority
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]